Facilitators and barriers to decentralized Long COVID platform clinical trials using repurposed drugs.

Authors

Marco Schito, Stacey Coe, Jaime Seltzer, Hannah E Davis, Vidula Sukhatme, Theodore W Johnson Ii, Judy Stone, Alexander D Truong, Linda N Geng, Tiffany A Walker

Published in

Frontiers in public health. Volume 14. Pages 1822376. Epub Sep 30, 2026.

Abstract

Long COVID is an emerging chronic condition that results in substantial impairments in quality of life, physical function, and ability to maintain gainful employment. There are no FDA-approved treatments for Long COVID, and recent institution-based clinical trials have not yielded effective treatments. Current standard of care involves trial-and-error drug repurposing that warrants evaluation in rigorous clinical trials. Here we describe potential advantages of decentralized repurposing drug trials as an alternative or complementary approach to institution-based trials. Additionally, we describe lessons learned when launching a local feasibility pilot trial that may inform the design of future decentralized trials in the Long COVID field.

PMID:
42876939
Bibliographic data and abstract were imported from PubMed on 15 Oct 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.